Metrics as of 10/15/2026, 10:36 AM (Berlin time), refresh in progress.
Biomea Fusion Stock
Biomea Fusion, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Michael J. Hitchcock
- Employees
- 37
- Market cap
- $63 M
- IPO
- 16/04/2021
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib…
Biomea Fusion stock: price history
1D
+5.5%
1W
-35.8%
1M
-51.1%
6M
-54.4%
YTD
-29.0%
1Y
-46.7%
2Y
-92.0%
5Y
-92.4%
10Y
–
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~20% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 14/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Biomea Fusion
Analyst assessment of Biomea Fusion
PRICE TARGET LOW
US$10.00
CONSENSUS
US$20.20
MEDIAN
US$19.00
PRICE TARGET HIGH
US$40.00
0
STRONG BUY
11
BUY
3
HOLD
0
SELL
0
STRONG SELL
14
TOTAL · Buy
As of: 14/10/2026
Biomea Fusion stock metrics
P/E
-1.75
P/B
5.18
EV/EBITDA
-0.84
RETURN ON EQUITY
-68.6%
NET MARGIN
0.0%
DEBT/EQUITY
0.07
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
93.5%
FLOAT SHARES
67,582,104
AVG. DAILY VOLUME (30D)
2,619,359
Institutional holders
Comparable stocks
Frequently asked questions about Biomea Fusion stock
What does Biomea Fusion do?
Biomea Fusion, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Michael J. Hitchcock, the company employs around 37 people.
The IPO was on 16/04/2021; the stock trades on NASDAQ under the ticker BMEA.
What do analysts say about Biomea Fusion stock?
14 analysts rate the stock, the consensus is Buy (as of 14/10/2026).
The average price target is US$20.20, ranging from US$10.00 to US$40.00, with a median of US$19.00.
This is an external assessment, not a statement by Market Jury.
When does Biomea Fusion report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly 20% stronger than usual.
Does Biomea Fusion pay a dividend?
No, Biomea Fusion currently does not pay a dividend.
Which stocks are comparable to Biomea Fusion?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Biomea Fusion stock analyzed?
Clicking "Analyze stock" lets five strategies assess Biomea Fusion against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.